Biotechnology Confirming it has a lot more to offer than just the highly successful COVID-19 vaccine Comirnaty, Germany’s BioNTech has presented data from its ongoing first-in-human Phase I/II trial evaluating the safety and preliminary efficacy of the company’s novel CAR-T cell therapy candidate, BNT211, in patients with advanced solid tumors. 11 April 2022